Skip to content
Business Company News, Medical Health Aged Care

LTR Pharma Announces Early Launch of Online Men’s Health Platform

JMM 2 mins read

Highlights:

  • Online telehealth platform facilitating regulated prescription of SPONTAN® has launched ahead of Q1 2025 target.

  • Australian men can now access SPONTAN through the TGA’s early access scheme through a strategic joint venture with Restorative Health Clinic Pty Ltd (RSHC), with bookings via rshealth.com.au.

  • Platform delivers comprehensive men's health services through online telehealth consultations. Early launch driven by strong market demand and operational readiness.

  • Growing proportion of Erectile Dysfunction (“ED”) prescriptions going online.

LTR Pharma Limited (ASX:LTP) (“LTR Pharma”, “the Company”) is pleased to announce that its joint venture partner, the Restorative Health Clinic (“RHC”), has launched an online healthcare platform ahead of the previously communicated Q1 2025 timeline. The platform, operated by RSHC, delivers comprehensive men’s health services through telehealth consultations.

Restorative Health Clinic Founder, Melissa Hadley Barrett, said: "We’re thrilled to launch our online booking, consultation, and prescribing platform for men’s health. Our team of specialists is ready to provide evidence-based care for erectile dysfunction, combining personalised treatment with improved accessibility for Australian men."

RSHC's early launch reflects a strong interest in accessible healthcare solutions. The platform combines RSHC's clinical expertise in men’s health with access to innovative treatments, including but not limited to, LTR Pharma's SPONTAN, providing Australian men with convenient access to healthcare professionals and evidence-based treatments.

LTR Pharma Executive Chairman, Lee Rodne, said: “This early launch by our joint venture partner demonstrates strong market demand for innovative healthcare solutions in men’s health. The platform provides an additional channel for delivering treatments, including SPONTAN, to Australian men via early access scheme pathways. We look forward to working with the RHC team to support the delivery of professional healthcare services in this growing online market." 

  1. The platform offers:

    • Professional medical consultations by experts in treating erectile dysfunction

    • Comprehensive therapeutic services in men’s health

    • Prescription and non-prescription treatments

    • Integrated health management solutions provided by RHC’s clinical team


About us:

LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.


Contact details:

info@janemorganmanagement.com.au

Media

More from this category

  • Medical Health Aged Care
  • 16/01/2025
  • 06:05
Royal Australian College of GPs

ADHD reform more urgent in NSW with psychiatrists’ workforce crisis

The Royal Australian College of GPs is urging the New South Wales Government to prioritise reforms to improve access to support and treatment for people with attention deficit hyperactivity disorder (ADHD) from GPs after the mass resignation of psychiatrists. Around 200 psychiatrists in NSW's public health system have submitted their resignations amid an ongoing pay dispute with the state government. RACGP New South Wales Chair Dr Rebekah Hoffman said: “GPs should be able to initiate and prescribe medications for people living with ADHD, and manage their care. Allowing GPs to give more support to people living with ADHD will improve…

  • Medical Health Aged Care
  • 16/01/2025
  • 05:00
GlaxoSmithKline

Local scientific discovery Omjarra (momelotinib) now TGA approved for Australians with rare bone marrow cancer

Embargoed: 06.00am Thursday 16th January 2025, MELBOURNE, AUSTRALIA Omjjara (momelotinib) was discovered by Melbourne scientists in 2005.1 Today’s TGA approval follows its recent FDA approval and makes it one of only a handful of original Australian scientific discoveries to secure both milestones.1-6 Omjjara is a once daily pill indicated to treat disease-related consequences of primary or secondary myelofibrosis including spleen enlargement and moderate to severe anaemia.7 Myelofibrosis is a rare bone marrow cancer with an average survival of 5-7 years.7-8 GSK Australia welcomes the Therapeutic Goods Administration (TGA) approval of Omjjara - a local scientific discovery now providing the first…

  • Medical Health Aged Care
  • 15/01/2025
  • 20:54
Glaxo SmithKline

Local scientific discovery Omjarra (momelotinib) TGA approved for Australians with rare bone marrow cancer

MELBOURNE PHOTO-FILMING OPPORTUNITY: THURSDAY 16TH JANUARY 2025 DATE: Thursday 16th January 2025 TIME: 10.30 – 11.30am LOCATION: 3 Torresdale Road, Toorak, Melbourne INTERVIEWEES: Prof…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.